MTOR and tumor of uterus: We also found that patients with uterine tumors had a lower DCR compared with those with an extrauterine location, both when considering all types of treatment (50.0% for n = 18 vs. 90.3% for n = 31, P = 0.004), and when considering mTOR inhibitors only (50.0% for n = 12 vs. 91.7% for n = 24, P = 0.009).